Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 11/20 | 0.57 |
| ▸ | DRD1 | P21728 | 6/20 | 0.57 |
| ▸ | DRD4 | P21917 | 5/20 | 0.57 |
| ▸ | DRD5 | P21918 | 5/20 | 0.57 |
| ▸ | DRD2 | P14416 | 4/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | DRD3 | P35462 | 4/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24440184 | 0.82 | LMNA (0.52) | HRH1DRD1DRD4DRD5DRD2 | |
| SCHEMBL12129191 | 0.79 | DRD1 (0.63) | HRH1DRD1DRD4DRD5DRD2 | |
| SCHEMBL18997033 | 0.79 | L3MBTL1 (0.56) | HPGDSMN1; SMN2TSHRL3MBTL1 | |
| SCHEMBL13449767 | 0.78 | KDM4E (0.41) | SMN1; SMN2L3MBTL1LMNA | |
| SCHEMBL12251017 | 0.78 | RIPK1 (0.44) | L3MBTL1 | |
| SCHEMBL12250933 | 0.78 | MAPT (0.58) | DRD2L3MBTL1HTR1AADRA1DADRA1A | |
| SCHEMBL2228334 | 0.78 | RIPK1 (0.44) | DRD1DRD4DRD5DRD2L3MBTL1 | |
| SCHEMBL10601013 | 0.77 | DRD2 (0.69) | HRH1DRD1DRD4DRD5DRD2 | |
| SCHEMBL5248169 | 0.76 | DRD1 (0.69) | HRH1DRD1DRD4DRD5DRD2 | |
| SCHEMBL12772057 | 0.76 | HRH1 (0.58) | HRH1DRD1DRD4DRD5DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100292289-A1 | TREATMENT OF METABOLIC SYNDROME WITH NOVEL AMIDES | AMPLA PHARMACEUTICALS INC. (US) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292289-A1 | TREATMENT OF METABOLIC SYNDROME WITH NOVEL AMIDES | GPR119, CPT1A, GLS2 | HRH1 2101/4885DRD1 3790/4885DRD4 4303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.